Biotechnology
Brii Bio Unveils New Data from Its Ongoing Phase 2 ENSURE Study at APASL 2025, Showcasing BRII-179's Unique Potential to Prime and Boost Higher HBsAg Loss Through Target Patient Identification
* Preliminary data from Cohort 4 of the ENSURE study supports a novel enrichment strategy to utilize BRII-179 to identify patients who are immune responders and have the potential to achieve higher HBsAg loss at EOT * 48-week EOT data from Cohort 1-3 of the ENSURE study clearly suggests the a...
2025-03-30 19:10
4820
Viva Biotech's Wholly-Owned Subsidiary Langhua Pharmaceutical Successfully Passes U.S. FDA On-Site Inspection
SHANGHAI, March 28, 2025 /PRNewswire/ -- Zhejiang Langhua Pharmaceutical Co., Ltd. ("Langhua Pharmaceutical"), a wholly-owned subsidiary of Viva Biotech Holdings ("Viva Biotech"), underwent a cGMP (Current Good Manufacturing Practices) on-site inspection by the U.S. Food and Drug Administration (...
2025-03-28 15:46
2354
IASO Bio Announces Approval of New Drug Application for Equecabtagene Autoleucel by the Macau Pharmaceutical Administration Bureau
SHANGHAI, NANJING, China and SAN JOSE, Calif., March 28, 2025 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies and biologics, today announced that the Pharmaceuti...
2025-03-28 12:55
2305
Shanton Reveals Topline Data from Phase 2b Study in Refractory Gout Patients
SAP-001 is Shanton's lead investigational compound with First- and Best-in-Class potential in uncontrolled gout SINGAPORE and PRINCETON, N.J., March 28, 2025 /PRNewswire/ -- Shanton Pharma, a clinical-stage biotech company developing a novel treatment for gout, today announced topline data of a ...
2025-03-28 09:00
2256
TraceLink Secures Top Honors with BSMA Supply Chain Excellence Award for Multienterprise Information Network Tower (MINT) Innovation
BOSTON, March 28, 2025 /PRNewswire/ -- TraceLink, the largest end-to-end digital network platform for intelligent orchestration of the supply chain, has been named a winner of the 2025 BSMA Supply Chain Management Innovation Award for its Multienterprise Information Network Tower (MINT) solution....
2025-03-28 03:49
2040
Viva Biotech Announces 2024 Annual Results: Significantly Rebounding in Performance with New Stage ahead, AI Leads to a New Era of Novel Drug R&D
Highlights of Annual Results for the Year Ended December 31, 2024 Revenue reached RMB1,986.7 million Gross profit amounted to RMB687.4 million Net profit recorded RMB222.0 million, a significant turnaround from a year ago Adjusted Non-IFRS net profit recorded RMB314.6 million, a YOY increase of nea...
2025-03-27 21:35
3982
First NDIN-Completed Akkermansia muciniphila for Muscle Health: BiomeNrich™ POST M005
CHICAGO, March 26, 2025 /PRNewswire/ -- CJ BIO's BiomeNrich™ POST M005 is the firstAkkermansia muciniphila-based ingredient to receive New Dietary Ingredient Notification (NDIN) acknowledgment from the U.S. Food and Drug Administration (FDA). This milestone confirms its safety and expands its pot...
2025-03-27 21:30
2513
Celltrion's STEQEYMA® (ustekinumab-stba), now added to the Costco Member Prescription Program
* STEQEYMA® (ustekinumab-stba) is Celltrion's biosimilar to STELARA® (ustekinumab), which was launched onMarch 12, 2025 * Celltrion's adalimumab-aaty was previously added to the Costco Member Prescription Program inAugust 2024 JERSEY CITY, N.J., March 27, 2025 /PRNewswire/ -- Celltrion, Inc.,...
2025-03-27 13:29
2126
Hyundai ADM Demonstrates Anti-Metastatic Effect of 'PenetriumTM' in TNBC Preclinical Study
– Simultaneous treatment of primary and metastatic tumors by eliminating pseudo-resistance SEOUL, South Korea, March 27, 2025 /PRNewswire/ -- Hyundai ADM Bio (KOSDAQ symbol 187660) announced on the 24th that its first-in-class pseudo-resistance-targeting agent, PenetriumTM, showed significant a...
2025-03-27 13:27
3203
Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2025 AACR Annual Meeting
SAN FRANCISCO and SUZHOU, China, March 27, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmun...
2025-03-27 09:17
3476
AnHorn Medicines Announces First Subject Dosed in AH-001 Phase I Clinical Trial in the United States
TAIPEI, March 26, 2025 /PRNewswire/ -- AnHorn Medicines, a pioneering AI-driven new drug discovery company, is pleased to announce that,AH-001, a first-in-class protein degrader for androgenetic alopecia (AGA), has officially entered Phase I clinical trial inthe United States. The first subject w...
2025-03-27 00:00
1830
Keymed Biosciences Announces Annual Results of 2024
CHENGDU, China, March 26, 2025 /PRNewswire/ -- March. 25, 2025, Keymed Biosciences Inc. (HKEX: 02162) announced its annual results of 2024, along with a corporate update. Rapid development of our pipeline products Stapokibart (CM310) (IL-4Rα antibody) Three new drug applications of Stapokibart...
2025-03-26 23:09
3091
Juncell Therapeutics to Present Preclinical Data on Innovative Pretreatment Regimen of TIL Therapy at AACR Annual Meeting 2025
SHANGHAI, March 26, 2025 /PRNewswire/ -- Shanghai Juncell Therapeutics Co., Ltd. (Juncell Therapeutics), a clinical-stage biotech developing innovative IL-2-independent Tumor-Infiltrating Lymphocyte (TIL) therapies for cancers, announced that a preclinical study of innovative pretreatment regimen...
2025-03-26 21:23
1873
Turn Biotechnologies Acquires ARMMs Vesicular Technology to Increase Access to Tissue Targets for its Epigenetic Reprogramming Therapies
* ARMMs brings precision medicine through targeted, non-viral vesicular delivery * Synergy of ARMMs and eTurna™ LNP platforms means company can deliver broad range of larger, more varied cargoes – including gene editors, proteins and RNA-based therapies * Two delivery technologies make poss...
2025-03-26 21:00
2337
Mabwell to Present results of 6 studies at the 2025 American Association for Cancer Research (AACR) Annual Meeting
SHANGHAI, March 26, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that it will present results of 6 studies as poster presentation at the AACR Annual Meeting to be held inChicago, USA, from April 25-30, 2025. The AA...
2025-03-26 20:00
2040
Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma
Results from Phase 2a Trial demonstrate a good safety and tolerability profile of VXM01 and Avelumab Combination Therapy in Glioblastoma, supporting further investigation of VXM01 BASEL, Switzerland, March 26, 2025 /PRNewswire/ -- Vaximm AG, a subsidiary of OSR Holdings, Inc. and a pioneering bi...
2025-03-26 19:16
2148
ANNOUNCEMENT OF ANNUAL RESULTS FOR 2024
Notable Progress in R&D and Commercialization Gross Profit Surging 68% FINANCIAL HIGHLIGHTS • Revenue was approximately RMB1,933.0 million, representing a year-on-year increase of 25.5%. • Gross profit was approximately RMB1,273.7 million, representing a year-on-year increase of 67.8%. • Res...
2025-03-26 19:08
3295
Innovent Announces 2024 Annual Results and Business Updates
First-ever positive profit, entering a new era of growth and global innovation SAN FRANSISCO and SUZHOU, China, March 26, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality med...
2025-03-26 19:02
4595
Antengene to Present Results From Four Cutting Edge Preclinical Studies at AACR 2025 with Focuses Including AnTenGagerTM TCEs and Synthetic Lethality
SHANGHAI and HONG KONG, March 26, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hem...
2025-03-26 16:28
2467
GenScript Biotech Earns EcoVadis Bronze Medal for the Second Consecutive Year, Ranking Above 83% of Companies
PISCATAWAY, N.J., March 26, 2025 /PRNewswire/ -- GenScript Biotech Corporation (GenScript), a global leader in life sciences research, manufacturing technologies and production services, has been awarded the EcoVadis Bronze Medal for the second year in a row, recognizing its strong sustainability...
2025-03-26 14:49
1846
Week's Top Stories
Most Reposted
Never Miss a Message: Agoda's Customer Support Now Travels With You
[Picked up by 327 media titles]
2026-02-24 12:00
NextFin Asia: A New Dedicated Fund for the Catapult: Inclusion SE Asia Program to Further Scale Inclusive Finance Fintechs in ASEAN
[Picked up by 311 media titles]
2026-02-23 08:00
Amadeus acquires SkyLink to accelerate the deployment of AI in travel
[Picked up by 309 media titles]
2026-02-26 19:57
HBX Group and Traveloka expand strategic partnership to deepen APAC supply and accelerate global distribution
[Picked up by 308 media titles]
2026-02-26 09:30
Klook and Osaka Convention & Tourism Bureau sign MoU to advance inbound tourism and foster socio-economic development throughout Osaka Prefecture
[Picked up by 302 media titles]
2026-02-24 16:13
Most Read
/C O R R E C T I O N -- Republic Power Group Limited (NASDAQ: RPGL)/
2026-02-20 06:36
9562
FY 2025 Results: Strong Commercial Growth, Focused Pipeline Investment
2026-02-20 07:27
8766